Catalent

Catalent, Inc., founded in 2007, has established itself as a powerhouse in the Biotechnology, Manufacturing, Pharmaceutical, and Supply Chain industries. Headquartered in the United States, this leading global contract development and manufacturing organization (CDMO) acts as a trusted partner for pharma, biotech, and consumer health companies worldwide.

Renowned for championing "missions that matter," Catalent focuses on patient-first principles, where they help bring over 100 new products to market annually. Their impressive track record includes supporting half of all FDA approvals over the past decade and producing over 60 billion doses per year at more than 40 global sites.

Their recent $600.00M Post-IPO Debt investment on 19 December 2023 underscores their financial robustness and commitment to leveraging advanced technologies that solve complex challenges. Investors eyeing opportunities in this sector will find Catalent's innovation, production scale, and patient-centric approach highly compelling.